Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superior efficacy over placebo in reducing fibromyalgia pain. These findings highlight the importance of rigorous clinical evidence before recommending CBD specifically for fibromyalgia management. Patients and clinicians should weigh the current lack of proven benefit against individual treatment goals and available alternatives.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides the first rigorous evidence base needed to determine whether CBD offers genuine clinical benefit beyond placebo for fibromyalgia pain, addressing a significant gap since CBD is already widely used off-label for this indication despite limited efficacy data. Given fibromyalgia’s poor response to conventional pharmacotherapies and the growing patient demand for cannabinoid treatments, establishing CBD’s true efficacy through this double-blind design could inform evidence-based prescribing guidelines and help clinicians counsel patients on realistic expectations. The safety and tolerability data generated will also be critical for risk-benefit assessment in a population that often requires long-term pain management strategies.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This randomised controlled trial provides valuable data on cannabidiol for fibromyalgia, a condition where patients often seek cannabis-based alternatives due to limited conventional options, though we should note the single-centre design and Danish population may limit generalisability to more diverse clinical settings. The double-blind, placebo-controlled methodology is methodologically sound, yet fibromyalgia’s heterogeneous pathophysiology and high placebo response rates in pain trials warrant cautious interpretation of any observed differences. Key confounders to consider include concurrent medications, sleep quality, and psychological factors, which the abstract does not fully detail and could substantially influence outcomes. If this trial demonstrates superiority of CBD over placebo with acceptable safety, it would support a reasonable discussion with carefully selected fibromyalgia patients about CBD as an adjunctive option, particularly those who have failed conventional analgesics or prefer to avoid opioids, though larger multicentre studies would be needed before considering it a first-line recommendation.